Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer

European Journal of Cancer

Volumn 44, Issue 3, 2008, Pages 391-399

  Young, O E ^a   Renshaw, L ^a   Macaskill, E J ^a   White, S ^a   Faratian, D ^a   Thomas, J St J ^a   Dixon, J M ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Fulvestrant; Ki67; Oestradiol; Oestrogen receptor; Premenopausal; Progesterone; Progesterone receptor

Indexed keywords

ALCOHOL; ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; FULVESTRANT; KI 67 ANTIGEN; LUTEINIZING HORMONE; PROGESTERONE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AMENORRHEA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; HUMAN TISSUE; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NAUSEA; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TASTE DISORDER; TUMOR BIOPSY; URINE ODOR; VAGINA DISCHARGE; XEROSTOMIA; BLOOD; BREAST TUMOR; COMPARATIVE STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 38749129651     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.11.007     Document Type: Article

References (11)

1. Jordan V.C., and Brodie A.M.H. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 (2007) 7-25
2. Wakeling A.E., Dukes M., and Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 51 (1991) 3867-3873
3. Howell A., Osborne C.K., Morris C., and Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 89 (2000) 817-825
4. Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61 (2001) 6739-6746
5. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
6. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
7. Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22 (2004) 1605-1613
8. Robertson J.F., Semiglazov V., Nemsadze G., et al. For the Study 41 Investigators. Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer 43 (2007) 64-70
9. Thomas E.J., Walton P.L., Thomas N.M., and Dowsett M. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod 9 (1994) 1991-1996
10. Jordan V.C., Fritz N.F., Langan-Fahey S., Thompson M., and Tormey D.C. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83 (1991) 1488-1491
11. Chatterton Jr. R.T., Zujewski J., Mateo E.T., et al. Effect of raloxifene on salivary sex steroid concentrations in premenopausal women. J Endocrinol 191 (2006) 599-604